Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 4/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.58 |
| ▸ | CCR2 | P41597 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17980518 | 0.90 | NR3C1 (0.71) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL17980531 | 0.88 | NR3C1 (0.57) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL17980879 | 0.87 | CCR2 (0.63) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL7079541 | 0.82 | CCR2 (0.68) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL8574855 | 0.81 | SPR (0.61) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL20413598 | 0.80 | RAB9A (0.53) | NR3C1POLBRAB9ASMN1; SMN2P4HTM | |
| SCHEMBL20413596 | 0.78 | NR3C1 (0.57) | SPRNR3C1RAB9ASMN1; SMN2 | |
| SCHEMBL5961458 | 0.78 | CCR2 (0.68) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL5070874 | 0.77 | SPR (0.61) | SPRNR3C1CCR2CCR5POLB | |
| SCHEMBL5069154 | 0.76 | SPR (0.52) | SPRNR3C1CCR2CCR5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | NR3C1, NR3C2, GRK3 | SPR 2583/4885NR3C1 1/4885CCR2 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.